Dendritic cell vaccines and obstacles to beneficial immunity in glioma patients

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 1, 2005, Pages 35-47

  Wheeler, Christopher J ^a   Black, Keith L ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cancer vaccine; Chemotherapy; Dendritic cell; Glioma; T cell; Thymus

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOPROTEIN GP 100; IMMUNOGLOBULIN G; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN 1; PROSTAGLANDIN E2; RECOMBINANT GAMMA INTERFERON; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN;

ANAPLASTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; CANCER CELL; CANCER IMMUNIZATION; CANCER RECURRENCE; CANCER SURVIVAL; CELL ACTIVATION; CELL LYSATE; CELLULAR IMMUNITY; CLINICAL TRIAL; CRANIOTOMY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; GLIOBLASTOMA; GLIOMA; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL MONITORING; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; OLIGODENDROGLIOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN FUNCTION; REVIEW; RISK REDUCTION; SIDE EFFECT; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; AUTOIMMUNITY; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; GLIOMA; HUMANS; MICE; SURVIVAL; THYMUS GLAND;

EID: 14244251038     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. DeAngelis LM: Brain tumors. N Engl J Med (2001) 344(2):114-123.
2. Davis FG, Kupelian V, Freels S, McCarthy B, Surawicz: T: Prevalence atimates for primary brain tumors in the United States by behavior and major histology groups. Neurooncol (2001) 3 3):152-158.
3. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE et al: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant gliorna trials. J Natl Cancer Inst (1993) 85(9):701-710.
4. Reavey-Cantwell JF, Haroun RI, Zahurak M, Clatterbuck RE, Parker RJ, Mehta R, Fruehauf JP, Brem H: The prognostic value of tumor markers in patients with glioblastoma multiforme: Analysis of 32 patients and review of the literature. J Neurooncol (2001) 55 3):195-204.
5. Stupp R, Hegi ME: Recent developments in the management of malignant glioma. In: Am Soc Clin Oncol Educational Book. Perry MC (Ed) American Society of Clinical Oncology, Alexandria, VA, USA (2003):779-788.
6. Kreth FW, Warnke PC, Scheremet R, Ostertag CB: Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg (1993) 78(5):762-766.
7. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K et al: A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg (2001) 95(2):190-198.
8. Fine HA, Dear KBG, Loeffler JS, Black PM, Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer (1993) 71 8):2585-2597.
9. Diete S, Treuheit T, Dietzmann K, Schmidt U, Wallesch CW: Sex differences in length of survival with malignant astrocytoma, but not with glioblastoma. J Neurooncol (2001) 53(1):47-49.
10. Burger PC: Pathologic anatomy and CT correlations in the glioblastoma multiforme. Appl Neurophysiol (1983) 46 1-4):180-187.
11. Feun LG, Wallace S, Yung WK, Lee YY, Leavens ME, Moser R, Savaraj N, Burgess MA, Plager C, Benjamin RS: Phase-I trial of intracarotid BCNU and cisplatin in patients with malignant intracerebral tumors. Cancer Drug Deliv (1984) 1(3):239-245.
12. Kapp JP, Sanford RA: Neurological deficit after carotid infusion of cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for malignant glioma: An analysis of risk factors. Neurosurgery (1986) 19(5):779-783.
13. Oldfield EH, Clark WC, Dedrick RL, Egorin MJ, Austin HA, DeVroom HD, Joyce KM, Doppman JL: Reduced systemic drug exposure by combining intraarterial cis-diamminedichloroplatinum(II) with hemodialysis of regional venous drainage. Cancer Res (1987) 47(7):1962-1967.
14. Ichikawa T, Tamiya T, Adachi Y, Ono Y, Matsumoto K, Furuta T, Yoshida Y, Hamada H, Ohmoto T: In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. Cancer Gene Ther (2000) 7 1):74-82.
15. Van Meir EG, Bellail A, Phuphanich S: Emerging molecular therapies for brain tumors. Semin Oncol (2004) 31(2 Suppl 4):38-46.
16. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ et al: Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res (1995) 56(14):3140-3148.
17. Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrand CJ, Hale LP, Small C, Dranoff G, Friedman AH et al: Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci USA (2000) 97(13):7503-7508.
18. Moscatello DK, Ramirez G, Wong AJ: A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res (1997) 57 8):1419-1424.
19. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona, F, Thompson RC, Riedinger MS, Zhang W et al: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration Cancer Res (2001) 61(3):842-847.
20. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T: Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother (2001) 50(7):337-344.
21. Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T, Narita M, Takahashi M, Tanaka R: Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: Results of a clinical phase I/II trial. Br J Cancer (2003) 89(7):1172-1179.
22. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ: Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific cytotoxic T cells in patients with malignant glioma. Cancer Res (2004) 64(14):4973-4979.
23. Inaba K, Metlay JP, Crowley MT, Steinman RM: Dendritic cells pulsed with protein antigens in vitro can prime sntigen-specific, MHC-restricted T cells in situ. J Exp Med (1990) 172(2):631-640.
24. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast MW, Deleo AB et al: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med (1995) 1(12):1297-1302.
25. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med (1996) 183(1):87-97.
26. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G: Proliferating dendritic cell progenitors in human blood. J Exp Med (1994) 180(1):83-93.
27. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med (1996) 2(1):52-58.
28. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 4 3):328-332.
29. Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC et al: Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate (1999) 38(1):73-78.
30. Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM, Troychak MJ, Salgaller ML, Boynton AL: Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment. Prostate (1999) 39(1):54-59.
31. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG: Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol (2001) 166(6):4254-4259.
32. Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzl A, Bartsch G, Thurnher M: Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol (1999) 161(3):777-782.
33. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefter U, Ullrich S, Muller CA, Becker V, Gross AJ et al Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med (2000) 6(3):332-336.
34. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG: Altered peptide ligand vaccination with Flt3 ligand expanded clendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA (2001) 98(15):8809-8814.
35. Morse MA, Nair S, Fernandez-Casal M, Deng Y, St Peter M, Williams R, Hobeika A, Mosca P, Clay T, Cumming RI, Fisher E et al: Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J Clin Oncol (2000) 18(23):3883-3893.
36. Panelli MC, Wunderlich J, Jeffries J, Wang E, Mixon A, Rosenberg SA, Marincola FM: Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother (2000) 23(4):487-498.
37. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE: Failure of cancer vaccines: The significant limitations of this approach to immunotherapy. Anticancer Res (2000) 20(4):2665-2676.
38. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 298(5594):850-854.
39. Weller M, Fontana A: The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T-cell apoptosis, and the immune privilege of the brain. Brain Res Rev (1995) 21 2):128-151.
40. Brooks WH, Roszman TL, Mahaley MS, Woosley RE: Immunobiology of primary Intracranial tumours. II Analysis of lymphocyte subpopulations in patients with primary brain tumours. Clin Exp Immunol (1977) 29(1):61-66.
41. Mahaley MS Jr, Brooks WH, Roszman TL, Bigner DD, Dudka L, Richardson S: Immunobiology of primary intracranial tumors. Part 1: Studies of the cellular and humoral general immune competence of brain-tumor patients. J Neurosurg (1977) 46(4):467-476.
42. Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, Fontana A: Immunosuppression and transforming growth factor-β in glioblastoma. Preferential production of transforming growth factor-β 2 J Immunol (1989) 143(10):3222-3229.
43. Black KL, Chen K, Becker DP, Merrill JE: Inflammatory leukocytes associated with increased immunosuppression by glioblastoma J Neurosurg (1992) 77(1):120-126.
44. Matsuda M, Petersson M, Lenkei R, Taupin JL, Magnusson I, Mellstedt H, Anderson P, Kiessling R: Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: Correlation with the stage of the disease. Int J Cancer (1995) 61 (6):765-772.
45. Reichert TE, Rabinowich H, Johnson JT, Whiteside TL: Mechanisms responsible for signaling and functional defects. J Immunother (1998) 21(4):295-306.
46. Lai P, Rabinowich H, Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL: Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res (1996) 2(1):161-173.
47. Rabinowich H, Suminami K, Reichert TE, Crowley-Nowick P, Bell M, Edwards R, Whiteside TL: Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer (1996) 68(3):276-284.
48. Morford LA, Elliott LH, Carlson SL, Brooks WH, Roszman TL: T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol (1997) 159(9):4415-4425.
49. Prins RM, Incardona F, Lau R, Lee P, Claus S, Zhang W, Black KL, Wheeler CJ: Characterization of defective CD4-CD8- T cells in murine tumors generated independent of antigen specificity. J Immunol (2004) 172(3):1602-1611.
50. Wiemels JL, Wiencke JK, Sison JD, Miike R, McMillan A, Wrensch M: History of allergies among adults with glioma and controls Int J Cancer (2002) 98(4):609-615.
51. Brenner AV, Linet MS, Fine HA, Shapiro WR, Selker RG, Black PM, Inskip PD: History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer (2002) 99 2):252-259.
52. Ueda R, Iizuka Y, Yoshida K, Kawase T, Kawakami Y, Toda M: Identification of a human glioma antigen: SOX6, recognized by patients' sera. Oncogene (2004) 23(7):1420-1427.
53. Wheeler CJ, Das A, Liu G, Yu JS, Black KL: Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res (2004) 10(16):5316-5326.
54. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol (1994) 12:337-365.
55. Rosenberg SA: Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today (1997) 18(4):175-182.
56. Liu G, Khong HT, Wheeler CJ, Yu JS, Black KL, Ying H: Molecular and functional analysis of tyrosinase-related protein (TRP -2 as a cytotoxic T lymphocyte target in patients with malignant glioma. J Immunother (2003) 26(4):301-312.
57. Wheeler CJ, Black KL, Liu G, Ying H, Yu JS, Zhang W, Lee PK: Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J Immunol (2003) 171(9):4927-4933.
58. Liu G, Yu JS, Zeng G, Yin D, Xie D, Black KL, Ying H: AIM-2: A novel tumor antigen is expressed and presented by human glioma cells. J Immunother (2004) 27(3):220-226.
59. Jager E, Ringhoffer M, Karbach J, Anand M, Oesch F, Knuth A: Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer (1996) 66(4):470-476.
60. Ohnmacht GA, Wang E, Mocellin S, Abati A, Filie A, Fetsch P, Riker AI, Kammula US, Rosenberg SA, Marincola FM: Short-term kinetics of tumor antigen expression in response to vaccination. J Immunol (2001) 167(3):1809-1820.
61. Ehtesham M, Black KL, Yu JS: Recent progress in immunotherapy for malignant glioma: Treatment strategies and results from clinical trials. Cancer Control (2004) 11(3):192-207.
62. Plautz GE, Miller DW, Barnett GH, Stevens GHJ, Maffet S, Kim J, Cohen PA, Shu S: T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res (2000) 6(6):2209-2218.
63. Kessels HW, Wolkers MC, Schumacher TN: Adoptive transfer of T-cell immunity. Trends Immunol (2002) 23(5 ):264-269.
64. Mackall CL, Gress RE: Thymic aging and T-cell regeneration Immunol Rev (1997) 160:91-102.
65. Berzins SP, Boyd RL, Miller JF: The role of the thymus and recent thymic migrants in the maintenance of the adult peripheral lymphocyte pool. J Exp Med (1998) 187(11):1839-1848.
66. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, Polis MA, Haase AT, Feinberg MB, Sullivan JL, Jamieson BD et al Changes in thymic function with age and during the treatment of HIV infection. Nature (1998) 396(6712):690-695.
67. Burger PC, Vogel FS, Green SB, Strike TA: Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer (1985) 56(5):1106-1111.
68. Berzins SP, Godfrey DI, Miller JFAP, Boyd RL: A central role for thymic emigrants in peripheral T cell homeostasis. Proc Natl Acad Sci USA (1999) 96(17):9787-9791.
69. Steffens CM, Al-Harthi L, Shott S, Yogev R, Landay A: Evaluation of thymopoiesis using T cell receptor excision circles (TRECs): Differential correlation between adult and pediatric TRECs and naive phenotypes. Clin Immunol (2000) 97(2):95-101.
70. Sempowski GD, Gooding ME, Liao HX, Le PT, Haynes BF: T cell receptor excision circle assessment of thymopoiesis in aging mice Mol Immunol (2002) 38(11):841-848.
71. Prins RM, Graf MR, Merchant RE, Black KL, Wheeler CJ: Thymic function and output of recent thymic emigrant T cells during intracranial glioma progression. J Neuro-Oncol (2003) 64 1-2):45-54.
72. Wheeler CJ, Yu JS, Black KL: Cellular immunity in the treatment of brain tumors. Clin Neurosurg (2004) 51 132-139.
73. McFarland RD, Douek DC, Koup RA, Picker LJ: Identification of a human recent thymic emigrant phenotype. Proc Natl Acad Sci USA (2000) 97(8):4215-4220.
74. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: From immunosurvelliance to tumor escape. Nat Immunol (2002) 3(11):991-998.
75. Burnet FM: The concept of immunological surveillance. Prog Exp Tumor Res (1970) 13:1-27.
76. Smyth MJ, Godfrey DI, Trapani JA: A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol (2001) 2 4):293-299.
77. Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 21 2):137-148.
78. Okada H, Lieberman FS, Edington HD, Witham TF, Wargo MF, Cai Q, Elder EH, Whiteside TL, Schold SC Jr, Pollack IF: Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: Preliminary observations in a patient with a favorable response to therapy. J Neuro-Oncol (2003) 64(1-2):13-20.
79. Leuraud P, Taillandier L, Medioni J, Aguirre-Cruz L, Criniere E, Marie Y, Kujas M, Golmard JL, Duprez A, Delattre JY, Sanson M, Poupon MF: Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations. Cancer Res (2004) 64(13):4648-4653.